Artisan Partners has liquidated its position in Cencora Inc. (NYSE:COR), citing a maturation of the pharmaceutical sourcing and distribution company's profit cycle as the primary driver behind the exit. The move, disclosed in Artisan's second-quarter 2026 investor commentary for its Global Opportunities Strategy, marks a notable shift in the fund's healthcare positioning.

Market Context

The announcement comes as Cencora shares continue to trade near the upper end of their 52-week range. On September 2, 2026, the stock closed at $336.36 per share, representing a 3.49% gain over the past month and a 14.92% return over the trailing 52 weeks. The company commands a market capitalization of approximately $63.16 billion, with shares trading between $244.82 and $377.54 over the past year.

Analysis

Artisan Global Opportunities Fund stated in its Q2 2026 letter that it ended investment campaigns in Cencora alongside Lonza Group and Medline during the quarter. The fund noted that while healthcare remains a core area of focus, management takes a pragmatic approach when individual companies fail to meet fundamental expectations or when profit cycles mature.

"In each case, stock-specific disappointments reduced our conviction in the remaining earnings opportunity, leading us to redeploy capital toward earlier stage profit cycles and higher conviction ideas across the portfolio," Artisan wrote. The firm described Cencora as a major distributor of branded, generic, and specialty drugs but determined that recent results reinforced its view that "the company's strongest period of earnings momentum is likely behind it."

The exit reflects Artisan's disciplined approach to valuation, with the fund stating it sees "fewer catalysts to accelerate growth" in Cencora and choosing instead to redeploy capital into earlier-stage profit cycles where it maintains greater conviction.

Key Numbers

- Share price on September 2, 2026: $336.36 per share

- Market capitalization: $63.16 billion

- 52-week return: +14.92%

- One-month return: +3.49%

- 52-week trading range: $244.82 - $377.54

What to Watch

Market participants will monitor Cencora's upcoming earnings reports for signs of accelerating revenue or profit growth that could attract new institutional buyers. The pharmaceutical distribution sector remains sensitive to drug pricing pressures and healthcare policy changes, factors that Artisan apparently weighed when determining the stock had moved beyond its peak conviction window.